FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware ...

CORPORATE OVERVIEW AUGUST 2021 Frank Bedu-Addo Ph.D. President & CEO 6 Nasdaq: PDSB Developing powerful, safe, versatile immunotherapies Forward-Looking Statements | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2021 Earnings Conference Call August 12, 2021 8:00 AM ET Company Participants Deanne Randolph - VP, Commercial Development & Head, IR Frank Bedu-Addo - President, CEO & Director Lauren Wood - Chief Medical Officer Seth Van Voorhees - CFO, Principal Financial & Accounting Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Leland Gershell - Oppenheimer & Co. Inc. Joseph Pantginis - H.C. Wainwright & Co. Robert LeBoyer - Noble Capital Markets Jam ...

CORPORATE OVERVIEW AUGUST 2021 Frank Bedu-Addo Ph.D. President & CEO 6 Nasdaq: PDSB Developing powerful, safe, versatile immunotherapies Forward-Looking Statements | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) (State or othe ...

CORPORATE OVERVIEW MAY 2021 Frank Bedu-Addo Ph.D. President & CEO 6 Nasdaq: PDSB Developing powerful, safe, versatile immunotherapies Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activities and timelines and market opportunities. All statements other than stateme ...

PDS Biotechnology Corp (NASDAQ:PDSB) Q1 2021 Earnings Conference Call May 13, 2021 8:00 AM ET Company Participants Deanne Randolph - VP, Commericial Development & Head, IR Frank Bedu-Addo - President, CEO & Director Lauren Wood - Chief Medical Officer Seth Van Voorhees - CFO, Principal Financial & Accounting Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co. Leland Gershell - Oppenheimer Operator Hello, and welcome to the PDS Biotechnology First Quarter 2021 Earnings Call and Webc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____________to_____________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) (State or other ...

Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to ________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 26-4231384 (State or other juri ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2020 Earnings Conference Call March 18, 2021 8:00 AM ET Company Participants Deanne Randolph - IR Frank Bedu-Addo - CEO Lauren V. Wood - CMO Seth L. Van Voorhees - CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright & Company Trevor Allred - Oppenheimer & Company Operator Greetings and welcome to the PDS Biotechnology's Fourth Quarter and Fiscal Year 2020 Earnings Call and Webcast. [Operator Instructions]. A question-and-answer session will foll ...